DY268 (Standard)
DY268 (Standard) is the analytical standard of DY268 (HY-110267). This product is intended for research and analytical applications. DY268 is a farnesoid X receptor (FXR) antagonist (IC50=7.5 nM). It inhibits FXR transactivation in a cell-based assay with an IC50 value of 468 nM. DY268 can be used in the study of drug-induced liver injury (DILI).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1609564-75-1
- Formule: C30H32N4O5S
- Masse moléculaire:560.66
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1609564-75-1
-
Masse moléculaire 560.66
-
Formule C30H32N4O5S
-
SMILES
O=C(C1=CN(CC2=CC(OC)=CC=C2)N=C1C3=CC=C(C)C=C3)NC4=CC=C(C)C(S(=O)(N5CCOCC5)=O)=C4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Yu DD, Lin W, Forman BM, Chen T. Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor. Bioorg Med Chem. 2014 Jun 1;22(11):2919-38. [Content Brief]
[2]. Kyounghwa Jung, et al. Farnesoid X Receptor Activation Impairs Liver Progenitor Cell-Mediated Liver Regeneration via the PTEN-PI3K-AKT-mTOR Axis in Zebrafish. Hepatology. 2021 Jul;74(1):397-410. [Content Brief]
[3]. Leah M Norona, et al. In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk. Arch Toxicol. 2020 Sep;94(9):3185-3200. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)